Eiger BioPharmaceuticals, Inc.
EIGRQ · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $10,408 | $49,121 | $176,171 | $345,882 |
| - Cash | $25,440 | $25,798 | $22,221 | $28,864 |
| + Debt | $41,203 | $40,199 | $32,539 | $32,514 |
| Enterprise Value | $26,171 | $63,522 | $186,489 | $349,532 |
| Revenue | $15,773 | $13,484 | $12,142 | $0 |
| % Growth | 17% | 11.1% | – | – |
| Gross Profit | $14,999 | $10,805 | $10,598 | -$645 |
| % Margin | 95.1% | 80.1% | 87.3% | – |
| EBITDA | -$68,741 | -$91,898 | -$29,495 | -$61,504 |
| % Margin | -435.8% | -681.5% | -242.9% | – |
| Net Income | -$74,963 | -$96,776 | -$33,917 | -$65,051 |
| % Margin | -475.3% | -717.7% | -279.3% | – |
| EPS Diluted | -50.78 | -69.74 | -29.98 | -69.34 |
| % Growth | 27.2% | -132.6% | 56.8% | – |
| Operating Cash Flow | -$74,548 | -$83,010 | -$71,517 | -$63,185 |
| Capital Expenditures | -$234 | -$340 | -$48,732 | -$258 |
| Free Cash Flow | -$74,782 | -$83,350 | -$120,249 | -$63,443 |